Atrial Fibrillation Management

Classification and Diagnosis

Atrial fibrillation (AF) is defined by the European Society of Cardiology as first diagnosed AF, paroxysmal AF, persistent AF, long-standing persistent AF, or permanent AF, with specific duration criteria for each category 1
The EHRA score is recommended for evaluating symptom severity in patients with AF 1
Documentation of heart rhythm regularity, precipitating factors, symptom severity, frequency, and duration of episodes is essential for assessing AF 1

The European Society of Cardiology recommends using the CHA₂DS₂-VASc score for stroke risk assessment in all patients with AF, with a strong recommendation for anticoagulation in men with a score ≥2 or women with a score ≥3 1, 2, 3
Patients with one 'major' risk factor or ≥2 'clinically relevant non-major' risk factors should receive oral anticoagulation, according to the European Society of Cardiology 1

The American College of Cardiology recommends monitoring INR weekly during initiation and monthly when stable for patients on vitamin K antagonists (VKAs), with a target INR of 2.0-3.0 and a time in therapeutic range >70% 4, 2
DOACs (apixaban, dabigatran, edoxaban, rivaroxaban) are preferred over VKAs except in patients with mechanical heart valves or mitral stenosis, according to the European Society of Cardiology 2

The American College of Cardiology recommends considering combination therapy (digoxin plus beta-blocker or calcium channel antagonist) to control rate at rest and during exercise in patients with AF 4
The European Society of Cardiology recommends targeting resting heart rate <110 beats/min (lenient control) as the initial approach 5
Beta-blockers, non-dihydropyridine calcium channel blockers (diltiazem, verapamil), and digoxin are suggested as first-line agents for rate control 5
Pharmacological cardioversion with flecainide or propafenone is recommended for recent-onset AF without structural heart disease, and vernakalant IV for recent-onset AF (avoiding in recent ACS, HFrEF, severe aortic stenosis) 2
Amiodarone IV is suggested for patients with severe LV hypertrophy, HFrEF, or coronary artery disease 2

Non-pharmacological therapy, such as ablation, should be considered when pharmacological therapy is insufficient, as recommended by the American College of Cardiology 4
Catheter ablation is recommended for paroxysmal or persistent AF resistant/intolerant to antiarrhythmic drugs 2
Catheter ablation is suggested as a first-line option for paroxysmal AF within a shared decision-making strategy 2
Concomitant surgical ablation during mitral valve surgery is recommended in patients with AF 2

Immediate electrical cardioversion is recommended for hemodynamically unstable patients, according to the American College of Cardiology 4
Anticoagulation for 3-4 weeks before and after cardioversion is recommended, or transesophageal echocardiography (TEE) can be used to rule out thrombus, as suggested by the American College of Cardiology 4

The European Society of Cardiology recommends maintaining optimal blood pressure with ACE inhibitors or ARBs as first-line therapy for hypertension 2
Optimizing heart failure therapy, especially in HFrEF, where ACE inhibitors/ARBs reduce AF incidence by 44% and beta-blockers by 33% 2
Targeting normal weight (BMI 20-25 kg/m²) for obesity management 2
Maintaining an active lifestyle (150-300 min/week moderate or 75-150 min/week vigorous activity) for physical activity 2
Avoiding binge drinking and excessive alcohol consumption 2
Considering evaluation and treatment for sleep apnea, though evidence for CPAP preventing AF is limited 2

Regular monitoring, including initial evaluation, ECG monitoring, medication monitoring, and anticoagulation reassessment, is recommended by the European Society of Cardiology 2, 5
Involving patients in treatment decisions, particularly when considering catheter ablation, taking into account procedural risks, likely benefits, and risk factors for AF recurrence 2, 3